APTEVO THERAPEUTICS INC (APVO) Stock Fundamental Analysis

NASDAQ:APVO • US03835L7029

6.71 USD
+0.12 (+1.82%)
Last: Feb 13, 2026, 08:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to APVO. APVO was compared to 522 industry peers in the Biotechnology industry. While APVO seems to be doing ok healthwise, there are quite some concerns on its profitability. APVO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • APVO had negative earnings in the past year.
  • APVO had a negative operating cash flow in the past year.
  • APVO had negative earnings in 4 of the past 5 years.
  • In the past 5 years APVO always reported negative operating cash flow.
APVO Yearly Net Income VS EBIT VS OCF VS FCFAPVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • APVO's Return On Assets of -103.54% is on the low side compared to the rest of the industry. APVO is outperformed by 76.05% of its industry peers.
  • APVO's Return On Equity of -160.72% is on the low side compared to the rest of the industry. APVO is outperformed by 65.13% of its industry peers.
Industry RankSector Rank
ROA -103.54%
ROE -160.72%
ROIC N/A
ROA(3y)-66.85%
ROA(5y)-56.8%
ROE(3y)-200.85%
ROE(5y)-609.94%
ROIC(3y)N/A
ROIC(5y)N/A
APVO Yearly ROA, ROE, ROICAPVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for APVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APVO Yearly Profit, Operating, Gross MarginsAPVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800 -1K

6

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, APVO has more shares outstanding
  • APVO has more shares outstanding than it did 5 years ago.
  • APVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APVO Yearly Shares OutstandingAPVO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
APVO Yearly Total Debt VS Total AssetsAPVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • APVO has an Altman-Z score of -16.05. This is a bad value and indicates that APVO is not financially healthy and even has some risk of bankruptcy.
  • APVO has a Altman-Z score of -16.05. This is amonst the worse of the industry: APVO underperforms 80.46% of its industry peers.
  • There is no outstanding debt for APVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.05
ROIC/WACCN/A
WACCN/A
APVO Yearly LT Debt VS Equity VS FCFAPVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 4.03 indicates that APVO has no problem at all paying its short term obligations.
  • APVO has a Current ratio (4.03) which is in line with its industry peers.
  • APVO has a Quick Ratio of 4.03. This indicates that APVO is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 4.03, APVO is in line with its industry, outperforming 49.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.03
Quick Ratio 4.03
APVO Yearly Current Assets VS Current LiabilitesAPVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 74.75% over the past year.
EPS 1Y (TTM)74.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.07%
EPS Next 2Y41.32%
EPS Next 3Y25.94%
EPS Next 5Y14.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APVO Yearly Revenue VS EstimatesAPVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2029 2030 2031 2032 50M 100M 150M
APVO Yearly EPS VS EstimatesAPVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1M -2M -3M

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for APVO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APVO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APVO Price Earnings VS Forward Price EarningsAPVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APVO Per share dataAPVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1K -2K -3K

4.3 Compensation for Growth

  • A more expensive valuation may be justified as APVO's earnings are expected to grow with 25.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.32%
EPS Next 3Y25.94%

0

5. Dividend

5.1 Amount

  • APVO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

APTEVO THERAPEUTICS INC

NASDAQ:APVO (2/13/2026, 8:00:00 PM)

6.71

+0.12 (+1.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-16
Earnings (Next)05-12
Inst Owners0.16%
Inst Owner Change-25.9%
Ins Owners0%
Ins Owner Change2.09%
Market Cap6.71M
Revenue(TTM)N/A
Net Income(TTM)-27.95M
Analysts82.86
Price Target7711.2 (114821.01%)
Short Float %N/A
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.43%
Min EPS beat(2)12.75%
Max EPS beat(2)90.1%
EPS beat(4)2
Avg EPS beat(4)-210.34%
Min EPS beat(4)-942%
Max EPS beat(4)90.1%
EPS beat(8)6
Avg EPS beat(8)-73.73%
EPS beat(12)9
Avg EPS beat(12)-32.62%
EPS beat(16)12
Avg EPS beat(16)6.37%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1700%
PT rev (3m)1700%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1700%
EPS NY rev (1m)-1700%
EPS NY rev (3m)-582.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB 0.39
EV/EBITDA N/A
EPS(TTM)-3412.48
EYN/A
EPS(NY)-29.38
Fwd EYN/A
FCF(TTM)-26.11
FCFYN/A
OCF(TTM)-26.11
OCFYN/A
SpS0
BVpS17.39
TBVpS17.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -103.54%
ROE -160.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.85%
ROA(5y)-56.8%
ROE(3y)-200.85%
ROE(5y)-609.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.03
Quick Ratio 4.03
Altman-Z -16.05
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.57%
EPS Next Y99.07%
EPS Next 2Y41.32%
EPS Next 3Y25.94%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-110.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-110.33%
OCF growth 3YN/A
OCF growth 5YN/A

APTEVO THERAPEUTICS INC / APVO FAQ

What is the ChartMill fundamental rating of APTEVO THERAPEUTICS INC (APVO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to APVO.


What is the valuation status of APTEVO THERAPEUTICS INC (APVO) stock?

ChartMill assigns a valuation rating of 1 / 10 to APTEVO THERAPEUTICS INC (APVO). This can be considered as Overvalued.


How profitable is APTEVO THERAPEUTICS INC (APVO) stock?

APTEVO THERAPEUTICS INC (APVO) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for APVO stock?

The Earnings per Share (EPS) of APTEVO THERAPEUTICS INC (APVO) is expected to grow by 99.07% in the next year.